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Abstract: Inflammatory bowel disease (IBD) is increasingly diagnosed among elderly persons (older than
60 years). Epidemiological studies show that late-onset IBD is characterized by predominance of colonic
disease, milder disease course, and less frequent occurrence of extraintestinal manifestations. However,
due to comorbidities, polypharmacy and reduced resistance to severe disease course elderly patients have
an increased risk of mortality. Drug treatment generally follows the same algorithms as in the younger IBD
patients. This is challenging for the treating physician as this population is usually underrepresented in
clinical trials and treatment outcomes as well as safety data on the elderly population are scarce. Choice of
drugs should consider risk of infections, skin cancer, lymphoma, and metabolic as well as cardiovascular
side effects. Considering comorbidities, surgical interventions such as colectomy with ileo-anal pouch
anastomosis for refractory ulcerative colitis can be performed safely provided that the anal sphincter
function is adequately maintained. Special attention should be given in this age group to general health
issues, including nutrition, vaccination, bone, muscle, and mental health as well as colorectal and skin
cancer screening.
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Abstract
Inflammatory bowel disease (IBD) is increasingly diagnosed 
among elderly persons (older than 60 years). Epidemiologi-
cal studies show that late-onset IBD is characterized by pre-
dominance of colonic disease, milder disease course, and 
less frequent occurrence of extraintestinal manifestations. 
However, due to comorbidities, polypharmacy and reduced 
resistance to severe disease course elderly patients have an 
increased risk of mortality. Drug treatment generally follows 
the same algorithms as in the younger IBD patients. This is 
challenging for the treating physician as this population is 
usually underrepresented in clinical trials and treatment out-
comes as well as safety data on the elderly population are 
scarce. Choice of drugs should consider risk of infections, 
skin cancer, lymphoma, and metabolic as well as cardiovas-
cular side effects. Considering comorbidities, surgical inter-
ventions such as colectomy with ileo-anal pouch anastomo-
sis for refractory ulcerative colitis can be performed safely 
provided that the anal sphincter function is adequately 
maintained. Special attention should be given in this age 
group to general health issues, including nutrition, vaccina-
tion, bone, muscle, and mental health as well as colorectal 
and skin cancer screening. © 2020 S. Karger AG, Basel
Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are 
both chronic inflammatory conditions of the gut related 
to a combination of genetic and environmental factors 
that impact on normal host – microbe interactions [1]. 
More and more importance is attributed to age-related 
immunosenescence which is associated with a relative 
systemic immunodeficiency compared with younger peo-
ple, with declines in functionality of both innate and adap-
tive immunity [2, 3]. Immune disturbances of the luminal 
mucosal immune system with ageing might result in an 
inability to mount protective immune responses to expo-
sure to new antigens [4]. These antigens are arising from 
commensal microorganisms, dietary products, and occa-





fraction of disease risk. Another factor may be endothe-
lial dysfunction that is considered an initial step in the 
pathogenesis of atherosclerosis in the general population. 
In inflammatory bowel disease (IBD), the inflammatory 
process leads to functional and structural changes in the 
vascular endothelium with an increase of leukocyte adhe-
siveness and leukocyte diapedesis and an increased vascu-
lar smooth muscle tone and procoagulant activity is ob-
served [5, 6]. In younger IBD patients, genetic factors are 
probably of greater importance than in older patients 
where cumulative exposure to environmental factors (ex-
posome) may have a more prominent role to drive disease 
development. So just 7% of CD subjects over the age of 60 
had a family history versus 16% of patients with disease 
onset before 16 years of age [7]. The term “exposome” was 
proposed to reflect a life-course of environmental influ-
ences beginning in utero and proceeding right through 
childhood to adulthood [8, 9]. Several factors such as diet, 
food additives (dietary emulsifiers), nanoparticles, air and 
water pollution, exposure to smoking, drugs (e.g., antibi-
otics and nonsteroidal anti-inflammatory drugs), infec-
tions, hypoxia, and others have been identified as envi-
ronmental contributors in this concept [10].
The Role of the Microbiota in Older IBD Patients
Intestinal dysbiosis is associated with several chronic 
conditions, including inflammatory diseases. IBD pa-
tients characteristically show a reduced biodiversity and 
altered composition of the intestinal microbiota with 
quantitatively increased abundance in bacteria which in-
clude Enterobacteriaceae, Pasteurellacaea, Veillonellaceae, 
and Fusobacteriaceae and decreased abundance in Erysip-
elotrichales, Bacteroidales, and Clostridiales which corre-
lates strongly with disease status [11, 12]. The microbiota 
of older people display greater inter-individual variation 
than that of younger adults [13]. Analysis of microbiota of 
elderly subjects with different residence locations (com-
munity, day-hospital, rehabilitation, or in long-term resi-
dential care) indicated that gut microbiota correlate to 
diet and health condition upon ageing [14]. Interestingly, 
the individual microbiota of people in long-stay care was 
significantly less diverse than that of community dwellers 
and loss of community-associated microbiota correlated 
with increased frailty. One of the potential factors where 
the microbiome is altered as a consequence of exposure to 
an environmental factor is use of antibiotics [15, 16]. Mi-
crobiome comparison between CD patients with and 
without antibiotic exposure indicates that antibiotic use 
amplifies the microbial dysbiosis associated with CD [11]. 
Modulating intestinal microbial composition therefore 
may represent a promising strategy for treatment of pa-
tients with IBD. Fecal microbiota transplantation and 
probiotics have been explored as promising candidates to 
reestablish microbial balance in IBD [17]. These microbi-
al-based therapies have demonstrated the ability to reduce 
both the dysbiotic environment and production of in-
flammatory mediators, thus inducing remission, especial-
ly in a part of UC patients [18–20]. Whether the changes 
of the microbiota seen in the elderly play a specific role for 
IBD disease course remains to be elucidated. Systematic 
analyses in cohorts of older patients and comparisons 
with younger cohorts have not been performed. As it has 
been postulated that the composition of the microbiota in 
the elderly may contribute to changes in the intestinal mu-
cosal innate immune system and immune reactions this 
analysis would indeed be important.
Epidemiology
Epidemiological data are often reported together for 
both forms of IBD, UC, and CD with most of IBD patients 
being diagnosed at young age. Several studies have shown 
a bimodal age distribution with a peak incidence in the sec-
ond to fourth decade and a second smaller peak in inci-
dence in the sixth to eighth decade [21, 22]. Due to world-
wide rising incidence of IBD and as a consequence of the 
ageing population an increase in the incidence and preva-
lence rate of IBD in the elderly is not surprising [23]. Fac-
tors such as urbanization, improved disease awareness, or 
improved diagnostics have been attributed to increase the 
number of elderly individuals living with IBD. Estimations 
for the incidence rates in UC in the elderly are ranging be-
tween 3 and 17 per 100,000 and in CD between 3 and 6 per 
100,000 [7, 24, 25]. A recent nationwide population-based 
study from Sweden reported an incidence rate of 35 per 
100,000 person years for IBD patients > 60 years or older 
with a clearly higher rate for UC compared to CD [26]. Sev-
eral population-based studies suggest that late-onset IBD 
has a milder clinical course with less frequent use of immu-
nomodulators as well as biologics, a lower rate of extraint-
estinal manifestations, and similar surgery rates when 
compared with younger IBD patients [7, 24–26]. However, 
especially correlating the use of drug treatments with the 
clinical course may be misleading as use of different drug 
classes may be influenced by comorbidities and polyphar-
macy in the elderly population and some drug classes may 
be avoided by the prescribing physicians for safety reasons. 
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As shown in the population-based study from Sweden el-
derly patients used fewer biologics and immunomodula-
tors but had a higher use of systemic corticosteroids com-
pared with pediatric and adult-onset IBD [26].
Clinical Presentation
The clinical presentation of patients with CD and UC 
differs between older and younger patients. Older-onset 
of CD is more frequently associated with isolated colonic 
inflammation and perianal fistulas and less small bowel 
and upper gastrointestinal disease [7, 25]. Inflammatory 
phenotype is more often observed in elderly CD patients 
than stricturing or penetrating disease. Elderly UC pa-
tients seem to have less isolated proctitis but more left 
sided and extensive colitis, and the disease location in el-
derly UC patients tends to remain stable with only a small 
fraction of patients showing disease extension at follow-
up [7]. A considerable delay in diagnosis of up to 6 years 
in the elderly compared to 2 years in younger adults has 
been observed [27]. Overall elderly IBD patients present 
with more subtle clinical symptoms. Elderly-onset CD 
subjects report less abdominal pain, systemic symptoms, 
and diarrhea, while subjects with a diagnosis of UC in 
older age report less abdominal pain and rectal bleeding 
[28]. In the differential diagnosis, the evaluation aims to 
exclude primarily malignancies (cancer and lymphoma) 
and infectious causes. But several other conditions of gas-
trointestinal inflammation can occur in the elderly that 
include diverticulitis, ischemic colitis, microscopic coli-
tis, drug-induced colitis (e.g., nonsteroidal anti-inflam-
matory drugs), or in case of a personal history of radiation 
therapy radiation-induced colitis (proctitis) and all these 
conditions should be excluded [29]. It is important to as-
sess the personal and medical history for preexisting con-
ditions such as cardiovascular diseases, diabetes mellitus, 
malignancies, functional and cognitive impairments, 
smoking history, and renal dysfunction which are preva-
lent comorbidities in elderly and which is crucial for cor-
rect assessment of the clinical condition and subsequent-
ly initiation of treatment.
Treatment
General Management and Treatment of Elderly IBD 
Patients
Management of elderly IBD patients has been insuf-
ficiently studied since older adults are underrepresented 
in clinical trials and no specific treatment algorithms 
have been developed for this age group. In recent years 
in many clinical trials, patients older than 65 were sys-
tematically excluded. Therefore, currently drug treat-
ment in the elderly follows principles that are established 
for younger IBD patients. Benefits of the chosen drug 
treatment should outweigh potential side effects and 
should consider specific safety issues. This is highly rel-
evant as in a recent Swiss IBD Cohort study addressing 
safety issues a positive correlation between the number 
of concomitantly administered IBD drugs and the occur-
rence of side effects requiring drug cessation was ob-
served [30]. Also in the elderly population, additional 
factors have to be considered as cardiovascular diseases, 
hypertension, diabetes mellitus, malignancies, functional 
and cognitive impairments, smoking history, and renal 
dysfunction are more prevalent [31]. Physicians should 
be at greater awareness that these patients may be treated 
already with different medications as polypharmacy in-
creases the risk of drug-drug interactions and may trigger 
or worsen concomitant diseases [31]. Age-dependent 
changes in liver and renal function and age-related body 
composition (increase of body fat, decrease of lean mus-
cle mass, hypoproteinemia) may impair the pharmacoki-
netics of medications and have to be considered while 
prescribing additional therapies in these patients. Spe-
cific attention has to be given also to infections in IBD 
patients on immunosuppressive therapy as they tend to 
occur more often due to age-related alterations in natural 
barriers and immunesenescence and are prone to a more 
serious clinical course [32].
In summary, treatment strategies in elderly IBD pa-
tients based on the location and severity of inflammation 
should implement the following goals: to induce and 
maintain remission to prevent disease-related complica-
tions, to avoid adverse events, and to improve quality of 
life. In the following sections, the commonly used IBD 
drug classes are discussed and information about side ef-
fects, drug-drug interactions, and specific recommenda-
tions is provided in Table 1.
5-Aminosalicylates
Oral and topical 5-aminosalicylates (5-ASA) are 
highly effective as induction and maintenance treat-
ment for UC but less effective in CD [33–36]. Interest-
ingly, a recent analysis indicates that mesalazine was 
the most frequent prescribed drug treatment for the el-
derly IBD patients and 80% of CD and 84% of UC pa-
tients have been treated with mesalazine within 10 years 





Table 1. Common side effects and drug-drug interactions for therapies used in elderly IBD patients
Drug class Substance(s) Side effects Drug-drug interactions Precautions and specific recommendations
Aminosalicylates Mesalazine
(5-ASA)
–  Rare (<0.1%) headache, dizziness, 
abdominal pain, bloating, diarrhea, 
nausea, vomiting, arthralgia, myalgia, 
skin rash
–  Very rare (<0.01%): nephrotoxicity, 
leukopenia, hepatitis
–  In combination with thiopurines 5-ASA 
increases the risk of leukopenia
–  5-ASA increases the anticoagulant activity 
of warfarin
Monitoring of laboratory parameters 
(blood count and renal function)
Corticosteroids Prednisone
Budesonide*
–  General occurrence of metabolic 
and endocrine side effects including 
diabetes, hypertension, adrenal 
suppression, gynaecomastia
–  Increased risk for osteoporosis, 
impaired wound healing, myopathy, 
aseptic necrosis of bones, 
gastrointestinal bleeding or 
perforation, infections, glaucoma, 
depression, delirium, psychosis
–  Concomitant use of CYP3A4 
inhibitors increase concentrations 
and effect of steroids
–  In combination with NSAIDS 
increased risk for peptic ulcer
–  Steroids modulate the activity of 
anticoagulant drugs, reduce the effects 
of antidiabetic agents, increase the 
hypokalemic effects of diuretics
–  Antiepileptic drugs (phenobarbital, 
phenytoin) reduce the efficacy of steroids
–  Pronounced adverse events in elderly 
patients; limit prescription to short  
applications (<3 months)
–  Clinical and laboratory monitoring: 
blood pressure, diabetes, eyes, 
coagulation




– Nausea, vomiting (5–10%)
– Flu-like symptoms (5%)
–  Leukopenia (<10%), agranulocytosis 
(<0.5%)
–  Pancreatitis (5–15%) hepatotoxicity 
(10%)
– Skin rash (<5%)
–  Increased risk of myelotoxicity in 
combination with allopurinol
–  Increased risk of leukopenia in 
combination with 5-ASA
–  Monitoring of laboratory parameters 
(blood count, liver function, lipase)








–  Abdominal discomfort, nausea, 
vomiting, diarrhea (>10%), stomatitis 
(1–10%)
–  Headache, fatigue (<10%), dizziness 
(<1%)
– Hair loss (<1%), skin rash (<10%)
–  Increased liver enzymes (>10%), 
chronic use with risk for liver cirrhosis
– Interstitial pneumonitis (1–10%)
– Myalgia, arthralgia (<1%)
–  Anemia, leukopenia, thrombocytopenia 
(<10%), agranulocytosis (<0.01%)
–  Various drug-drug interactions due to 
alterations in plasma protein binding, 
renal clearance, and intestinal resorption
–  Increased methotrexate concentration 
in combination with 5-ASA, NSAIDs, 
antibiotics (penicillin, tetracyclines, 
sulfonamides)
–  Methotrexate decreases theophylline 
clearance, increases the effect of 
coumarin derivatives
–  Monitoring of laboratory parameters 
(blood count and liver enzymes)
–  Supplementation with folic acid 
5 mg 24 h after methotrexate
–  Specific attention to liver disease 
(hepatotoxicity) and renal insufficiency
Calcineurin
inhibitor
Cyclosporine –  Headache, migraine (15%), tremor 
(10–20%), paresthesia (<10%)
–  Abdominal discomfort, nausea, 
vomiting, gingival hyperplasia (>10%)
–  Renal insufficiency (10–50%), 
hypertension (15–40%), increase 
of liver enzymes (<10%)
–  Leukopenia (5–10%), hyperlipidemia 
(>10%)
–  Hypertrichosis (>10%), acne, rash 
(1–10%)
– Increased risk for infections
–  Drug interactions can occur with drugs 
that are substrates of CYP3A4 and 
P-glykoprotein
–  Avoid concomitant use of drugs with 
nephrotoxic properties
–  Use not recommended in elderly 
patients
– Check for hypertension
– Avoid grape fruit juice








–  Headache, fatigue, dizziness, fever 
(1–10%)
–  Abdominal discomfort, nausea 
(1–10%) 
–  Increased risk of infections (1–10%),  
including opportunistic infections 
(<0.1%)
–  Infusion reactions, allergic reactions 
(5–10%)
–  Skin rash (5–10%), various skin 
diseases (1–5%), TNFα blocker 
induced psoriasis (<1%)
–  Lupus-like syndrome (<1%), 
anaphylaxis (<1%)
–  In general better side effect profile 
of subcutaneous application 
formulations
– Local irritation at injection site
Concomitant use of immunomodulators
may suppress the formation of antidrug
antibodies
– Screening before treatmenta
– Monitoring of laboratory parameters
–  Contraindicated in cardiac 
insufficiency (NYHA III–IV)
–  Use with caution in patients with chronic 
liver disease, neurological pathology, or 
history of malignancy, especially lym-
phoma
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use in older adults might be explained by its excellent 
tolerability and the limited number of alternatives, es-
pecially for mild to moderate disease course. In patients 
with ulcerative proctitis or left-sided colitis, a combina-
tion of oral and topical mesalazine is more effective 
than either alone [38]. For better adherence rates, once-
daily dosing is recommended as compliance is an im-
portant issue in the elderly. Problems with self-admin-
istration of topical agents especially with suppositories, 
enemas, and foam may limit usage in some elderly pa-
tients due to impaired mobility and incontinence [35, 
39, 40].
5-ASA are generally considered safe and efficacious, 
the most common adverse reactions include nausea and 
vomiting, headache, abdominal pain, and rash [38]. 
Nephrotoxicity is a rare adverse event in patients on 
5-ASA treatment and specific attention should be given 
to patients with underlying kidney disease. Renal func-
tion should be checked before and during therapy. Leu-
kopenia can occur when 5-ASA agents are used in com-
bination with thiopurines, due to an increase in 6-thio-
guanine levels, the active metabolite of azathioprine, and 
6-mercaptopurine (6-MMP) [41, 42].
Steroids
As fast-acting drugs corticosteroids are often used as 
induction agents in both UC and CD for rapid control of 
symptoms. A significant use of corticosteroids is reported 
in elderly IBD patients [7, 43, 44], and a recent analysis 
demonstrates that a proportion of 20–40% of IBD patients 
are treated with corticosteroids during the first 5  years 
following IBD diagnosis [26]. Therefore, metabolic (i.e., 
diabetes mellitus, dyslipidemia, weight gain, lipodystro-
phy) and cardiovascular (i.e., hypertension, cardiovascu-
lar events) adverse events have to be considered specifi-
cally in this patient group and repetitive or prolonged 
courses of corticosteroids should be avoided [45]. Pro-
longed use of steroid-based therapies may worsen differ-
ent clinical conditions such as preexisting diabetes melli-
tus, hypertension, infections (e.g., pneumonia), eye lens 
cataract, or may cause mental state alterations [31, 46]. 
Attention has to be given also to corticosteroid-induced 
osteoporosis and the risk of bone fractures. In Swiss IBD 
patients, corticosteroids and age were the most relevant 
risk factors for decreased bone mineral density [47]. The 
risk of gastrointestinal bleeding is increased in elderly pa-
tients especially when corticosteroids are given concomi-
Drug class Substance(s) Side effects Drug-drug interactions Precautions and specific recommendations
Integrin
inhibitors
Vedolizumab –  Nasopharyngitis (10%) upper 
respiratory and intestinal infections 
(1–10%)
– Headache (10%), arthralgia (>10%)
– Abdominal discomfort, nausea (1–10%)
–  Allergic infusion reactions (<1%), 
fever (1–10%)
Pharmacokinetic studies with thiopurines
or methotrexate do not indicate relevant
changes in pharmacokinetics of
vedolizumab
– Screening before treatmenta
– Monitoring of laboratory parameters
– No signal for PML
Anti-IL-12/23 Ab Ustekinumab – Headache, fatigue, dizziness (5–10%)
–  Nasopharyngitis (5–10%), lower 
respiratory tract infections (<1%), 
cellulitis (<1%)
–  Abdominal discomfort, vomiting, 
nausea, diarrhea (<10%)
– Arthralgia (5–10%), urticaria (<1%)
– Local irritation at injection site (1–10%)
Attention to combination therapies with
other immunosuppressive drugs due to
potentiation of immunosuppression
and risk for severe infections
– Screening before treatmenta
– Monitoring of laboratory parameters
– Rare observation: reversible PRES
Small
molecule
Tofacitinib – Headache, fatigue (<10%)
–  Upper/lower respiratory tract and 
urinary tract infections (1–10%)
– Herpes zoster infection (5–10%)
–  Abdominal discomfort, diarrhea, 
nausea (<10%)
–  Hypertension (<10%), hyperlipidemia 
(<1%)
– Skin rash (<10%), arthralgia (<10%)
Drug interactions can occur with
drugs that are substrates of CYP3A4
and CYP2C19
–  Laboratory monitoring (blood count, 
lipid status, creatinine kinase)
–  Check VZV IgG, if positive, 
consider Shingrix vaccination
–  Specific precautions in patients with 
increased risk for pulmonary embolism 
especially tofacitinib 10 mg bid
* Less systemic side effects due to high first-pass effect in the liver.
a Screening for active or latent tuberculosis including chest X-ray, Hepatitis B (HBs ag; anti-HBc ab), HIV serology, blood count, liver function; vaccination with live vaccines prior 
to initiation if indicated.







tantly with nonsteroidal anti-inflammatory drugs. This 
suggests that screening for risk factors for upper gastroin-
testinal bleeding should be routinely done and subsequent 
prophylactic PPI treatment installed [48]. Due to the high 
first-pass metabolism in the liver, budesonide or modified 
release formulations of budesonide have fewer systemic 
effects compared with prednisone and should be consid-
ered in mildly-to-moderately active disease in elderly IBD 
patients [49–51]. However, it has to be considered that 
side effects of topical steroids may be more frequent in the 
elderly patients.
Immunosuppressive Drugs: Thiopurines, 
Methotrexate, Cyclosporine
Thiopurines are purine antimetabolites that inhibit 
cell proliferation especially of lymphatic cells and are ef-
fective to maintain remission in CD and UC [38, 52]. No 
differences in efficacy have been noted with the use of 
thiopurines in the elderly [53]. However, the use of thio-
purines in the elderly needs very careful consideration 
and monitoring due to potential drug interactions, in-
creased risk of lymphoma, non-melanoma skin cancer, 
and infection [54]. Dose-dependent adverse events in-
clude nausea, vomiting, and dyspepsia and occurrence of 
leucopenia (in severe cases agranulocytosis) and eleva-
tion of transaminases; therefore, regular monitoring with 
complete blood count and liver function tests is required 
[55]. Determining the thiopurine methyltransferase ac-
tivity may reduce the time to therapeutic drug levels and 
can help to identify patients at risk for myelosuppression 
and to prevent toxicity [55]. Allopurinol may enhance the 
myelosuppressive effects of thiopurines by blocking thio-
purine methyltransferase activity. Blocking of this enzy-
matic activity with allopurinol with concomitant reduc-
tion of azathioprine (to 25–33% of normal weight based 
dose) is used in some patients with increased methylated 
6-MMP levels (“hypermethylators”) to enhance thera-
peutic efficacy. Dose-independent adverse event pancre-
atitis, flu like symptoms, and occurrence of rash can be 
observed in a minority of patients treated with thiopu-
rines. The risk of lymphoma in IBD patients treated with 
azathioprine and 6-MMP was found increased especially 
in the elderly population [54, 56]. The CESAME cohort 
indicated that the risk significantly increases above the 
age of 65 [57]. There does not seem to exist a significant 
gender difference concerning the distribution of lympho-
ma except for the hepatosplenic T-cell lymphoma cases 
which were seen predominantly in younger men and not 
so relevant in the elderly population [58]. A recent study 
associated increasing age, especially in older men, with an 
increased risk of urinary tract cancers in patients with 
IBD receiving thiopurines [59]. In addition, patients on 
immunosuppressive medications have a substantially el-
evated risk of non-melanoma skin cancer [60]. IBD pa-
tients using thiopurines seem to have a moderately in-
creased risk for non-melanoma skin cancer which is pro-
portional to therapy duration and which decreases or 
returns to baseline risk after discontinuing therapy [61]. 
Younger patients with IBD using thiopurines seem to be 
at greater risk of developing non-melanoma skin cancer, 
which suggests early implementation of skin cancer 
screening recommendations and strict application of sun 
protection. In summary, there are ongoing discussions 
whether use of thiopurines in the elderly population is 
safe. In general, it is recommended to perform a very 
careful risk/benefit analysis given the increased cancer 
risk in the elderly population and thiopurines should be 
used with caution in this age group.
The use of methotrexate monotherapy in patients with 
IBD is of controversial discussion. Methotrexate has not 
been studied exclusively in elderly IBD patients, but ret-
rospective cohort data indicate limited use in the elderly 
with similar outcomes compared to young patients [62]. 
In the rheumatology literature in older patients with rheu-
matoid arthritis (RA), similar responsiveness of metho-
trexate to that in younger patients was observed [63]. For 
patients with CD induction and maintenance of remis-
sion/clinical response with 10–25 mg methotrexate sub-
cutaneous weekly was shown [64, 65]. The effect seems to 
be more pronounced in combination with anti-TNF ther-
apy [66]. For patients with UC methotrexate was not 
found to be better than placebo in the induction, mainte-
nance of remission, or preventing relapses of UC in pa-
tients who achieved steroid-free response [67, 68]. Atten-
tion should be given to symptoms of general malaise, gas-
trointestinal complaints, and asymptomatic increase of 
liver enzymes [62, 69]. Use of folic acid supplementation 
is mandatory in patients treated with methotrexate.
Cyclosporine is used for rescue therapy in severe UC 
patients. It is not recommended in elderly IBD patients 
given the risk profile for comorbidities such as hyperten-
sion and renal disease in this patient group [54, 70]. If 
cyclosporine is used, monitoring of the renal function 
should be assured.
Biologics: TNFα Blockers, Anti-Integrins, and Anti  
IL-12/23
Anti-TNF agents are used in moderate to severe CD 
and UC and are effective in inducing clinical and endo-
scopic remission, decreasing rates of hospitalization and 
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surgery. Although some data suggest a lower rate of short-
term clinical response in elderly IBD patients to anti-
TNFs there is no evidence that the efficacy of medical 
treatment in elderly IBD patients differs from that in 
younger adult patients [54, 71, 72]. In patients > 65 years 
similar clinical remission rates of 59% in UC and 65% in 
CD after approximately 2 years of treatment on inflix-
imab or adalimumab compared to younger patients was 
observed [73]. Long-term clinical response to anti-TNF 
agents seems to be similar between those initiating the 
drug before and after age 65 [71]. But patients older than 
age 60 at the time of initiation of anti-TNF therapy are at 
higher risk for discontinuation of therapy probably due 
to side effects such as increased vulnerability to infectious 
complications [74]. This goes in line with the finding that 
older corticosteroid-responsive patients were less likely 
to be treated with an anti-TNF than younger patients 
[72]. There are no specific data addressing the effective-
ness of combination therapy, particularly anti TNFα 
treatment in combination with thiopurines in the elderly.
The most prominent adverse events due to anti TNFα 
therapy include infusion reactions, abdominal discom-
fort, infections (including bacterial, viral, fungal, and op-
portunistic infections) as well as rare occurrence of auto-
immune, dermatological disorders, cardiac, and neuro-
logical conditions [75]. Cottone et al. [73] reported a 12% 
risk of serious infection in the elderly on anti-TNF agents, 
including pneumonia and sepsis. The increased use of 
TNFα in clinical practice raised concerns about a possible 
association with cancer. Data from registries regarding 
patients with RA showed that the overall incidence of 
cancer is similar to that observed in the general popula-
tion [76, 77]. However, anti-TNFα treatment in combina-
tion with immunomodulators is associated with an in-
creased risk of developing non-Hodgkin lymphoma in 
adult CD patients [78, 79]. As main risk factors for devel-
oping lymphoproliferative disorder older age, male sex, 
and longer duration of IBD were identified [57, 80]. Also, 
anti-TNF therapy has been associated in IBD patients 
with an increased risk of melanoma (OR 1.88; 95% CI 
1.08–3.29), which was not confirmed in a large nested 
Canadian case-control study [81, 82]. The risk to develop 
recurrent malignancy on TNF-α inhibitor therapy in pa-
tients with previous malignancies cannot be definitively 
answered as studies have shown contradictory findings 
[83]. In the British biologics register for RA patients, 
treatment with TNFα inhibitor seems not to increase re-
current malignancy as the recurrent malignant incidence 
was not higher than the control group of RA patients with 
prior malignancy not treated with biologics [84].
In summary, anti-TNF-α agents are contraindicated in 
patients with cardiac insufficiency and must be used with 
caution in patients with chronic liver disease, neurologi-
cal pathology, or history of malignancy, especially lym-
phoma in patients on combination with immunomodu-
lators [85].
Newer biological therapies include the anti-integrin 
blocker vedolizumab and the monoclonal antibody 
ustekinumab blocking the IL-12/23 axis. The gut-specific 
integrin blocker vedolizumab has been shown to effec-
tively induce remission and to maintain remission in pa-
tients moderate to severe CD and UC [86, 87]. In a small 
study, the efficacy and safety of VDZ in elderly patients 
(> 60 years old) with UC and CD were shown with clinical 
remission rate of 41% at week 52 [88]. In a pooled post 
hoc analysis, vedolizumab shows a favorable safety profile 
with low incidence rates of serious infections, infusion-
related reactions, and malignancies over an extended 
treatment period. No increased risk of any infection or 
serious infection was associated with vedolizumab expo-
sure [89]. Risk factors associated with serious infection 
for vedolizumab treated patients with CD were younger 
age, concurrent corticosteroids, and opiate use. No cases 
of progressive multifocal leukoencephalopathy related to 
the JC virus reactivation were reported as it was a concern 
during the use of its nonselective anti-integrin predeces-
sor natalizumab.
Similarly, ustekinumab that effectively induces and 
maintains remission in patients with moderate to severe 
CD seems to offer a favorable infectious safety profile. 
Randomized clinical trials demonstrated so far no in-
creased infection frequency compared to placebo [90].
Small Molecules: Tofacitinib
Tofacitinib, an oral, small-molecule Janus kinase in-
hibitor, was shown to be more effective as induction and 
maintenance therapy than placebo in moderately to se-
verely active UC [91]. In a safety analysis of patients with 
moderate to severe UC treated with tofacitinib, addition-
al serious infectious risk was observed, especially a dose 
relationship with herpes zoster infection [92]. Experience 
from patients with RA receiving tofacitinib demonstrates 
that in most cases (93%) herpes zoster was classified as 
nonserious, and the majority of patients (94%) had in-
volvement of only 1 dermatome [93]. Shingrix a new her-
pes zoster subunit vaccine containing recombinant vari-
cella-zoster virus glycoprotein E was found to reduce the 
risks of herpes zoster and postherpetic neuralgia among 
adults 70 years of age or older [94]. Herpes zoster-related 





to be reduced by approximately 90% in adult ≥70 years 
[95]. Although Shingrix has not yet been tested in immu-
nosuppressed individuals this inactivated recombinant 
herpes zoster vaccination may become a recommended 
vaccine before starting tofacitinib.
Surgery
The indications for surgery are not different between 
elderly and younger adult patients in both CD and UC. 
Elderly UC patients were less likely to undergo surgery 
compared to younger UC patients and have lower rates of 
total colectomy as well as segmental colectomy [96–99]. 
In CD patients, the necessity for surgery appears to be 
lower with a higher age at the onset of disease [100, 101]. 
In severe UC, early surgery has been recommended for 
elderly patients in order to reduce complications [102]. In 
UC patients requiring pouch surgery, the surgical ap-
proach is not different from younger adult patients and a 
favorable functional outcome is observed when the pa-
tient had a good anal sphincter function documented pre-
operatively [103, 104]. However, in case of decreased anal 
sphincter function, the option of permanent ileostomy 
instead of ileal anal pouch should be discussed in elderly 
patients [54]. Overall, elderly IBD patients were found to 
have a longer postoperative stay and a higher in-hospital 
mortality rate [105]. Age is independently associated with 
postoperative morbidity and mortality with preoperative 
transfusion, emergency operation, and weight loss pre-
dicting morbidity for those 80 years of age and older 
[106]. The rate of major postoperative complications and 
death among elderly patients has improved in the last de-
cades, which are probably due to availability of more ef-
fective IBD medical management, higher emphasis on 
improving preoperative nutritional status, early mobili-
zation, and/or an increased tendency to perform surgery 
earlier in the course of disease [107, 108].
General Considerations and Recommendations for 
the Management of Elderly Patients (Table 2)
Nutrition
Malnutrition is being observed in IBD due to any 
combination of inadequate dietary intake associated with 
feeling unwell, altered nutritional requirements, and/or 
impairment of nutrient absorption [109]. Malnutrition 
has been reported in patients with IBD with a prevalence 
rate of 14% for patients with CD and 5.7% with UC and 
with clearly increased frequencies for hospitalized pa-
tients [110, 111]. Decreased food intake, nutrient malab-
sorption, increased intestinal loss, increased energy ex-
penditure, as well as drug interactions may contribute to 
protein-calorie malnutrition and can be in consequence 
a considerable risk factor for infectious and other dis-
ease-specific complications. Localization, extension of 
inflammation, disease activity, as well as resection of 
bowel are some crucial risk factors for deficiencies of 
macronutrients and of specific micronutrients such as 
trace elements as well as vitamins and should be moni-
tored when suspected and supplemented if deficiency is 
observed.
Osteoporosis
Risk of osteoporosis and osteoporotic fractures is in-
creased in all IBD patients. Besides age-related bone loss 
elderly IBD patients are at increased risk of osteoporosis 
and related fractures due to malnutrition, vitamin D de-
ficiency, corticosteroid treatment, and reduced physical 
activity [47]. Preventive measures such as supplementa-
tion with vitamin D/calcium, adequate treatment of the 
underlying disease, and monitoring with osteodensitom-
etry are required.
Infections
Due to the modification of the immune system in IBD 
patients, infectious complications – both common and 
opportunistic – have to be considered during therapy 
with immunomodulators or biologics. Compared to the 
non-IBD population, IBD patients are at increased risk of 
infectious complications including influenza, pneumo-
nia, herpes zoster, Clostridium difficile infection, CMV 
colitis, and others [112–114]. Opportunistic infections 
are associated with anti-TNFs, and the risk of opportu-
nistic infection increases with age with patients over 
50 years carrying a 3 times increased risk [115]. Severe 
infections that require admission to the intensive care 
unit, multiple organ dysfunction, or which fulfill system-
ic inflammatory response criteria are associated with in-
creased morbidity and mortality. In patients with viral 
illness experiencing either a severe primary infection or 
reactivation, biological therapy should be interrupted un-
til appropriate therapy is instituted and clinical improve-
ment is observed. With mild infections biological treat-
ment can be continued [116]. Therefore, assessing an in-
dividual patient’s risk of therapeutic complications is the 
first step to improving safety with biologic agents. Treat-
ment guidelines recommend that patients be tested for 
tuberculosis, hepatitis B, HIV and when appropriate, vac-
cinations should be given before initiation of biologicals 
or immunosuppressive treatment [85].
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Vaccinations
Immunosenescence makes the elderly more suscepti-
ble to infections and in consequence complications of in-
fections. The vaccination guidelines for elderly IBD pa-
tients are similar to those for patients without CD or UC. 
When possible, patients with IBD should receive age-ap-
propriate vaccinations before initiation of immunosup-
pression [117]. It has to be considered that immunosup-
pressed patients > 60 years appear to respond less well to 
vaccinations. In general, inactivated vaccinations are safe 
for administration in immunosuppressed individuals. 
Recommendations for vaccinations in the elderly are pre-
sented in Table 3. Specifically, older patients should be 
given the influenza vaccine annually and the pneumococ-
cal vaccine with a booster revaccination after 5 years [118]. 
As mentioned before, Shingrix a new herpes zoster sub-
unit vaccine may become a recommended vaccine before 
starting tofacitinib. However, patients prescribed biologi-
cals and other immunosuppressants should avoid live vac-
cines, although following the guidelines of the Infectious 
Disease Society of America live vaccines in those on low 
dose immunosuppression (prednisone ≤20 mg/day, aza-
thioprine ≤3.0 mg/kg/day, MMP ≤1.5 mg/kg/day, metho-
trexate ≤0.4 mg/kg/week) may be considered [119].
Thrombotic Complications
Spontaneous reporting (pharmacovigilance database 
VigiBase) of cases of pulmonary embolism and thrombo-
embolism in connection with infliximab should increase 
the awareness of physicians for such events/complica-
Table 2. Recommendations for the management of elderly IBD patients
General considerations
– Assess symptom severity, physical exam, laboratory evaluations, and if indicated endoscopic evaluation
– Choose IBD therapy according individualized goals of care
– Check for concomitant medication regularly
– Consider comorbidities, potential interactions, side effects of treatment
– Monitor for potential drug-drug interactions, check for adherence
– Address smoking cessation (beneficial also for elderly patients)
– Communicate with primary care physician and other specialists
Monitoring
– Regular office visits
– Be aware of adverse effects to therapy, especially infections
– Laboratory testing (blood count, albumin, renal function, CRP)
– Include check for vitamins (vitamin b12, folic acid, vitamin d), trace elements, and iron status (if indicated) at regular intervals
– Bone densitometry (in patients with long and/or severe inflammation and/or steroid usage or additional risk factors)
– If appropriate calcium and vitamin D supplementation
– Screening for depression or sleep disturbances
– If appropriate ophtalmological exam
– Be aware of thrombotic risk or complications in elderly IBD patients
Nutrition and physical activity
– Nutritional optimization, consider dietary counseling if appropriate
– Documentation of weight at regular intervals
– Promote the importance of physical activity
Cancer screening
–  Regular colonoscopy screening every 10 years, starting at the age of 50. Consider frequent screening in high-risk individuals 
(family history of CRC, severe and extensive colitis, past dysplasia, or primary sclerosing cholangitis)
–  Elderly-onset IBD patients might be at higher risk for CRC, screening starting 1–2 years after diagnosis and should be balanced 
with disease severity, comorbidities, and life expectancy
– In individuals on immunosuppressive medication skin inspection by dermatologist yearly
– In women on immunosuppressive therapy annual cervical cancer screening should be implemented
Vaccinations
– Follow guidelines for elderly individuals (Table 3)
– Avoid vaccinations with live vaccines in the immunosuppressed patient





tions, especially in IBD patients treated with newer drugs. 
In general, the thrombotic risk in elderly patients is prob-
ably underestimated, but thrombotic complications in 
case of hospitalization represent an increased risk in IBD 
patients and need prevention. Antithrombotic prophy-
laxis should therefore be considered in all hospitalized 
elderly patients with IBD. Treatment of venous thrombo-
embolism in IBD should follow established antithrom-
botic therapy options taking into account a potentially 
increased risk of bleeding [54, 120]. 
Cancer Screening
Thiopurine therapy seems to moderately increase the 
risk for nonmelanoma skin cancer and the risk of lym-
phoma in patients with IBD [54, 56, 121]. Both azathio-
prine and 6-MMP are known photosensitizers that re-
duce the minimal erythema dose for UV-A radiation and 
also play a role in generation of reactive oxygen species 
[122, 123]. The increased risk for nonmelanoma skin can-
cer does not seem to be daily dose-dependent but some 
studies show a duration-dependent (cumulative dose) 
trend for increasing risk [124]. Therefore, the importance 
of sun protective measures and benefits of regular skin 
cancer screening should be considered.
In a population-based cohort of nearly 30,000 women 
with IBD reported increased risk for cervical dysplasia in 
women with IBD and increased risk of cervical cancer 
[125]. In a retrospective analysis of women under 65 years 
of age with IBD, 15% had abnormal Pap smears compared 
to 5% among normal patient populations [126]. There-
fore, women with IBD on immunosuppressive therapy 
should undergo annual cervical cancer screening [117].
Table 3. Recommended vaccinations for elderly patients with IBD (adapted from [117])
Guidelines for administration
Inactivated vaccines
Tdap A single dose of Tdap recommended at age 11 through 64 years; single dose of Td
(tetanus/diphtheria) every 10 years
Hepatitis A Titer check HAV ab; if negative 2 doses at 0 and 6 months
Hepatitis B Titer check HBs ab; if negative 3 doses at 1, 1–2, and 4–6 months; optional titer check 1 month after the last 
dose
Streptococcus pneumoniaea
(PCV13 and PPSV 23)
Patients at age 65 years or older if at least 5 years have elapsed since their previous PPSV23 dose
Neisseria meningitidis 2 or 3 doses depending on vaccine in high-risk situations (e.g., splenectomy, travel to endemic
areas, military, employee day/preschool care)
Herpes zoster 2 doses Shingrix (2–6 months apart)
Influenza Annual immunization with inactivated tri- or quadrivalent influenza vaccine for patients 65 and
older; live-attenuated intranasal influenza vaccine contraindicated in immunosuppressed patients
Tick borne encephalitis 3 doses (0, 2–4 weeks and 6–12 months; booster every 10 years, recommended in
endemic areas with potential exposition to ticks
Live vaccinesb
MMR 2 doses (>28 days apart)
Varicella If unknown vaccination history or exposure, check VZV IgG titer; if neg 2 doses (4–6 weeks apart)
Yellow fever Attenuated live vaccine; consult with a travel medicine or infectious disease specialist
prior to travel to tropical areas
Samonella typhi Oral attenuated live vaccine consult with a travel medicine or infectious disease specialist prior to travel to 
tropical areas
a If no previous vaccination, PCV13 followed by a dose of PPSV23 after 2–12 months; if received 1 or more doses of PPSV23 should receive 
PCV13 one or more years after PPSV23; another dose of PPSV23 should be administered 5 years after the initial PPSV23 dose. 
b Live vaccines are generally contraindicated in immunosuppressed patients; prevaccination washout period of immunosuppressive therapy 
should be >3 months, post-vaccination period before initiating immunosuppressive therapy 1 month.
IBD, inflammatory bowel disease; Tdap, tetanus, diphteria, pertussis; MMR, measles-mumps rubella.
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Colorectal Cancer Screening and Tumor Risk in the 
Elderly
Colorectal cancer (CRC) screening is recommended in 
all individuals beyond age 50 and for IBD patients, start 
of screening colonoscopy is advised 8 years after onset of 
IBD symptoms [127]. However, several publications sug-
gest that onset of screening in elderly IBD patients should 
be initiated earlier. In a population-based study, age at 
diagnosis was a significant risk factor for early-onset CRC 
cases with 35% of older patients with both IBD and CRC 
developed the CRC within 8 years of the IBD diagnosis 
[128]. A large cohort study found a much shorter interval 
to diagnosis of flat dysplasia in elderly patients with UC 
[129]. Other factors that influence the frequency of colo-
noscopies for surveillance in IBD patients include family 
history of CRC, severe and extensive colitis, past dyspla-
sia, or primary sclerosing cholangitis [127]. In the elderly, 
CRC screening should be balanced with disease severity, 
comorbidities, and life expectancy.
Conclusion
The medical management of elderly patients with IBD 
is challenging with respect to diagnosis, drug therapy, 
and surgical treatment. In recent years, patients older 
than 65 were systematically excluded from clinical trials 
and therefore important information about therapy suc-
cess, outcome, adverse events, and general epidemiolog-
ical information is often extrapolated from younger IBD 
populations. It is questionable whether this is ethical. 
With our ageing population, it needs to be changed ur-
gently to gain better evidence for the treatment of the 
elderly.
Acknowledgment
No funding was provided for this manuscript.
Disclosure Statement
The authors have no conflicts of interest to declare related to 
this manuscript.
Author Contributions
All authors conceptualized the extent of the manuscript. P.H. 
and G.R. drafted the initial manuscript. All authors critically re-
viewed and approved the final manuscript as submitted.
References
 1 Jostins L, Ripke S, Weersma RK, Duerr 
RH, McGovern DP, Hui KY, et al.; Interna-
tional IBD Genetics Consortium (IIBDGC). 
Host-microbe interactions have shaped the 
genetic architecture of inflammatory bowel 
disease. Nature. 2012 Nov; 491(7422): 119–24.
 2 Cambier J. Immunosenescence: a problem 
of lymphopoiesis, homeostasis, microenvi-
ronment, and signaling. Immunol Rev. 2005 
Jun; 205(1): 5–6.
 3 Linton PJ, Dorshkind K. Age-related chang-
es in lymphocyte development and function. 
Nat Immunol. 2004 Feb; 5(2): 133–9.
 4 Clegg A, Young J, Iliffe S, Rikkert MO, Rock-
wood K. Frailty in elderly people. Lancet. 
2013 Mar; 381(9868): 752–62.
 5 Cibor D, Domagala-Rodacka R, Rodacki T, 
Jurczyszyn A, Mach T, Owczarek D. Endo-
thelial dysfunction in inflammatory bowel 
diseases: Pathogenesis, assessment and im-
plications. World J Gastroenterol. 2016 Jan; 
22(3): 1067–77.
 6 Steyers CM 3rd, Miller FJ Jr. Endothelial 
dysfunction in chronic inflammatory dis-
eases. Int J Mol Sci. 2014 Jun; 15(7): 11324–
49.
 7 Charpentier C, Salleron J, Savoye G, Fumery 
M, Merle V, Laberenne JE, et al. Natural his-
tory of elderly-onset inflammatory bowel 
disease: a population-based cohort study. 
Gut. 2014 Mar; 63(3): 423–32.
 8 Niess JH, Kaymak T, Hruz P. [The Role of 
the Exposome in the Emergence of Chronic 
Inflammatory Bowel Diseases]. Ther 
Umsch. 2019 Jan; 75(5): 261–70.
 9 Rogler G, Vavricka S. Exposome in IBD: re-
cent insights in environmental factors that 
influence the onset and course of IBD. In-
flamm Bowel Dis. 2015 Feb; 21(2): 400–8.
10 Maaser C, Langholz E, Gordon H, Burisch J, 
Ellul P, Ramirez VH, et al. European Crohn’s 
and Colitis Organisation Topical Review on 
Environmental Factors in IBD. J Crohn’s 
Colitis. 2017 Aug; 11(8 suppl_1): 905–20.
11 Gevers D, Kugathasan S, Denson LA, 
Vázquez-Baeza Y, Van Treuren W, Ren B, et 
al. The treatment-naive microbiome in new-
onset Crohn’s disease. Cell Host Microbe. 
2014 Mar; 15(3): 382–92.
12 Yilmaz B, Juillerat P, Øyås O, Ramon C, Bra-
vo FD, Franc Y, et al.; Swiss IBD Cohort In-
vestigators. Microbial network disturbances 
in relapsing refractory Crohn’s disease. Nat 
Med. 2019 Feb; 25(2): 323–36.
13 Claesson MJ, Cusack S, O’Sullivan O, 
Greene-Diniz R, de Weerd H, Flannery E, et 
al. Composition, variability, and temporal 
stability of the intestinal microbiota of the 
elderly. Proc Natl Acad Sci USA. 2011 Mar; 
108 Suppl 1: 4586–91.
14 Claesson MJ, Jeffery IB, Conde S, Power SE, 
O’Connor EM, Cusack S, et al. Gut micro-
biota composition correlates with diet and 
health in the elderly. Nature. 2012 Aug; 
488(7410): 178–84.
15 Hviid A, Svanström H, Frisch M. Antibiotic 
use and inflammatory bowel diseases in 
childhood. Gut. 2011 Jan; 60(1): 49–54.
16 Shaw SY, Blanchard JF, Bernstein CN. As-
sociation between the use of antibiotics and 
new diagnoses of Crohn’s disease and ulcer-
ative colitis. Am J Gastroenterol. 2011 Dec; 
106(12): 2133–42.
17 Basso PJ, Câmara NO, Sales-Campos H. Mi-
crobial-Based Therapies in the Treatment of 
Inflammatory Bowel Disease - An Overview 






18 Moayyedi P, Surette MG, Kim PT, Libertuc-
ci J, Wolfe M, Onischi C, et al. Fecal Micro-
biota Transplantation Induces Remission in 
Patients With Active Ulcerative Colitis in a 
Randomized Controlled Trial. Gastroenter-
ology. 2015 Jul; 149(1): 102–9.e6.
19 Paramsothy S, Kamm MA, Kaakoush NO, 
Walsh AJ, van den Bogaerde J, Samuel D, et 
al. Multidonor intensive faecal microbiota 
transplantation for active ulcerative colitis: a 
randomised placebo-controlled trial. Lan-
cet. 2017 Mar; 389(10075): 1218–28.
20 Paramsothy S, Paramsothy R, Rubin DT, 
Kamm MA, Kaakoush NO, Mitchell HM, et 
al. Faecal Microbiota Transplantation for 
Inflammatory Bowel Disease: A Systematic 
Review and Meta-analysis. J Crohn’s Colitis. 
2017 Oct; 11(10): 1180–99.
21 Robertson DJ, Grimm IS. Inflammatory 
bowel disease in the elderly. Gastroenterol 
Clin North Am. 2001 Jun; 30(2): 409–26.
22 Russel MG, Stockbrügger RW. Epidemiolo-
gy of inflammatory bowel disease: an up-
date. Scand J Gastroenterol. 1996 May; 31(5): 
417–27.
23 Molodecky NA, Soon IS, Rabi DM, Ghali 
WA, Ferris M, Chernoff G, et al. Increasing 
incidence and prevalence of the inflamma-
tory bowel diseases with time, based on sys-
tematic review. Gastroenterology. 2012 Jan; 
142(1): 46–54.e42.
24 Jeuring SF, van den Heuvel TR, Zeegers MP, 
Hameeteman WH, Romberg-Camps MJ, 
Oostenbrug LE, et al. Epidemiology and 
Long-term Outcome of Inflammatory Bow-
el Disease Diagnosed at Elderly Age-An In-
creasing Distinct Entity? Inflamm Bowel 
Dis. 2016 Jun; 22(6): 1425–34.
25 Lakatos PL, David G, Pandur T, Erdelyi 
Z,  Mester G, Balogh M, et al. IBD in the 
 elderly population: results from a popula-
tion-based study in Western Hungary, 
1977-2008. J Crohn’s Colitis. 2011 Feb; 
5(1): 5–13.
26 Everhov AH, Halfvarson J, Myrelid P, Sachs 
MC, Nordenvall C, Soderling J, et al. Inci-
dence and Treatment of Patients Diagnosed 
With Inflammatory Bowel Diseases at 60 
Years or Older in Sweden. Gastroenterology. 
2018 Feb; 154(3): 518–28.e15.
27 Katz S, Pardi DS. Inflammatory bowel dis-
ease of the elderly: frequently asked ques-
tions (FAQs). Am J Gastroenterol. 2011 
Nov; 106(11): 1889–97.
28 Ananthakrishnan AN, Shi HY, Tang W, Law 
CC, Sung JJ, Chan FK, et al. Systematic Re-
view and Meta-analysis: Phenotype and 
Clinical Outcomes of Older-onset Inflam-
matory Bowel Disease. J Crohn’s Colitis. 
2016 Oct; 10(10): 1224–36.
29 Pardi DS, Loftus EV Jr, Camilleri M. Treat-
ment of inflammatory bowel disease in the 
elderly: an update. Drugs Aging. 2002; 19(5): 
355–63.
30 Godat S, Fournier N, Safroneeva E, Juillerat 
P, Nydegger A, Straumann A, et al.; Swiss 
IBD Cohort Study Group. Frequency and 
type of drug-related side effects necessitat-
ing treatment discontinuation in the Swiss 
Inflammatory Bowel Disease Cohort. Eur J 
Gastroenterol Hepatol. 2018 Jun; 30(6): 612–
20.
31 Arnott I, Rogler G, Halfvarson J. The Man-
agement of Inflammatory Bowel Disease in 
Elderly: Current Evidence and Future Per-
spectives. Inflamm Intest Dis. 2018 Jul; 2(4): 
189–99.
32 Butter M, Weiler S, Biedermann L, Scharl M, 
Rogler G, Bischoff-Ferrari HA, et al. Clinical 
manifestations, pathophysiology, treatment 
and outcome of inflammatory bowel diseas-
es in older people. Maturitas. 2018 Apr; 110: 
71–8.
33 Akobeng AK, Zhang D, Gordon M, Mac-
Donald JK. Oral 5-aminosalicylic acid for 
maintenance of medically-induced remis-
sion in Crohn’s disease. Cochrane Database 
Syst Rev. 2016 Sep; 9:CD003715.
34 Bokemeyer B, Hommes D, Gill I, Broberg P, 
Dignass A. Mesalazine in left-sided ulcer-
ative colitis: efficacy analyses from the PO-
DIUM trial on maintenance of remission 
and mucosal healing. J Crohn’s Colitis. 2012 
May; 6(4): 476–82.
35 John ES, Katz K, Saxena M, Chokhavatia 
S,  Katz S. Management of Inflammatory 
Bowel Disease in the Elderly. Curr Treat 
Options Gastroenterol. 2016 Sep; 14(3): 
285–304.
36 Lichtenstein GR, Feagan BG, Cohen RD, 
Salzberg BA, Diamond RH, Langholff W, et 
al. Drug therapies and the risk of malignancy 
in Crohn’s disease: results from the TRE-
ATTM Registry. Am J Gastroenterol. 2014 
Feb; 109(2): 212–23.
37 Ha CY, Katz S. Clinical outcomes and man-
agement of inflammatory bowel disease in 
the older patient. Curr Gastroenterol Rep. 
2013 Feb; 15(2): 310.
38 Kornbluth A, Sachar DB; Practice Parame-
ters Committee of the American College of 
Gastroenterology. Ulcerative colitis practice 
guidelines in adults: American College Of 
Gastroenterology, Practice Parameters 
Committee. Am J Gastroenterol. 2010 Mar; 
105(3): 501–23.
39 Shah BJ, Chokhavatia S, Rose S. Fecal incon-
tinence in the elderly: FAQ. Am J Gastroen-
terol. 2012 Nov; 107(11): 1635–46.
40 Taleban S. Challenges in the Diagnosis and 
Management of Inflammatory Bowel Dis-
ease in the Elderly. Curr Treat Options Gas-
troenterol. 2015 Sep; 13(3): 275–86.
41 Fangbin Z, Xiang G, Minhu C, Liang D, 
Feng X, Min H, et al. Should thiopurine 
methyltransferase genotypes and pheno-
types be measured before thiopurine ther-
apy in patients with inflammatory bowel 
disease? Ther Drug Monit. 2012 Dec; 34(6): 
695–701.
42 Lowry PW, Franklin CL, Weaver AL, 
 Szumlanski CL, Mays DC, Loftus EV, et 
al.  Leucopenia resulting from a drug 
 interaction between azathioprine or 6-mer-
captopurine and mesalamine, sulphasala-
zine, or balsalazide. Gut. 2001 Nov; 49(5): 
656–64.
43 Nguyen GC, Sheng L, Benchimol EI. Health 
Care utilization in elderly onset inflamma-
tory bowel disease: a population-based 
study. Inflamm Bowel Dis. 2015 Apr; 21(4): 
777–82.
44 Stepaniuk P, Bernstein CN, Nugent Z, Singh 
H. Characterization of inflammatory bowel 
disease in elderly hospitalized patients in a 
large central Canadian Health region. Can J 
Gastroenterol Hepatol. 2015 Jun-Jul; 29(5): 
274–8.
45 Fardet L, Fève B. Systemic glucocorticoid 
therapy: a review of its metabolic and cardio-
vascular adverse events. Drugs. 2014 Oct; 
74(15): 1731–45.
46 Cerullo MA. Expect psychiatric side effects 
from corticosteroid use in the elderly. Geri-
atrics. 2008 Jan; 63(1): 15–8.
47 Schüle S, Rossel JB, Frey D, Biedermann L, 
Scharl M, Zeitz J, et al.; Swiss IBD cohort 
study. Prediction of low bone mineral den-
sity in patients with inflammatory bowel dis-
eases. United European Gastroenterol J. 
2016 Oct; 4(5): 669–76.
48 Ruiz B, Aguirre U, Estany-Gestal A, Rodella 
L, Ruiz P, Figueiras A, et al. Only full adher-
ence to proton pump inhibitors protects 
against drug-induced upper gastrointestinal 
bleeding. Eur J Clin Pharmacol. 2018 Nov; 
74(11): 1503–11.
49 D’Haens G, Verstraete A, Cheyns K, Aerden 
I, Bouillon R, Rutgeerts P. Bone turnover 
during short-term therapy with methylpred-
nisolone or budesonide in Crohn’s disease. 
Aliment Pharmacol Ther. 1998 May; 12(5): 
419–24.
50 Rutgeerts P, Löfberg R, Malchow H, Lamers 
C, Olaison G, Jewell D, et al. A comparison 
of budesonide with prednisolone for active 
Crohn’s disease. N Engl J Med. 1994 Sep; 
331(13): 842–5.
51 Travis SP, Danese S, Kupcinskas L, Alexeeva 
O, D’Haens G, Gibson PR, et al. Once-daily 
budesonide MMX in active, mild-to-moder-
ate ulcerative colitis: results from the ran-
domised CORE II study. Gut. 2014 Mar; 
63(3): 433–41.
52 Lichtenstein GR, Hanauer SB, Sandborn 
WJ;  Practice Parameters Committee of 
American College of Gastroenterology. 
Management of Crohn's disease in adults. 
Am J Gastroenterol. 2009 Feb; 104(2): 465–
83.
53 Chaparro M, Ordás I, Cabré E, Garcia-San-
chez V, Bastida G, Peñalva M, et al. Safety of 
thiopurine therapy in inflammatory bowel 
disease: long-term follow-up study of 3931 
patients. Inflamm Bowel Dis. 2013 Jun; 
19(7): 1404–10.
54 Sturm A, Maaser C, Mendall M, Karagiannis 
D, Karatzas P, Ipenburg N, et al. European 
Crohn’s and Colitis Organisation Topical 
Review on IBD in the Elderly. J Crohns Coli-
tis. 2017 Mar; 11(3): 263–73.
Elderly IBD Patient 13Digestion
DOI: 10.1159/000503099
55 Mottet C, Schoepfer AM, Juillerat P, Cosnes 
J, Froehlich F, Kessler-Brondolo V, et al. Ex-
perts Opinion on the Practical Use of Aza-
thioprine and 6-Mercaptopurine in Inflam-
matory Bowel Disease. Inflamm Bowel Dis. 
2016 Nov; 22(11): 2733–47.
56 Lemaitre M, Kirchgesner J, Rudnichi A, 
 Carrat F, Zureik M, Carbonnel F, et al. 
 Association Between Use of Thiopurines 
or Tumor Necrosis Factor Antagonists 
Alone or in Combination and Risk of Lym-
phoma in Patients With Inflammatory 
Bowel Disease. JAMA. 2017 Nov; 318(17): 
1679–86.
57 Beaugerie L, Brousse N, Bouvier AM, 
 Colombel JF, Lémann M, Cosnes J, et 
al.;  CESAME Study Group. Lymphoprolif-
erative disorders in patients receiving 
 thiopurines for inflammatory bowel dis-
ease: a prospective observational cohort 
study. Lancet. 2009 Nov; 374(9701): 1617–
25.
58 Kotlyar DS, Lewis JD, Beaugerie L, Tierney 
A, Brensinger CM, Gisbert JP, et al. Risk of 
lymphoma in patients with inflammatory 
bowel disease treated with azathioprine and 
6-mercaptopurine: a meta-analysis. Clin 
Gastroenterol Hepatol. 2015 May; 13(5): 
847–58.e4.
59 Bourrier A, Carrat F, Colombel JF, Bouvi-
er AM, Abitbol V, Marteau P, et al.; CESA-
ME study group. Excess risk of urinary 
tract  cancers in patients receiving thiopu-
rines for inflammatory bowel disease: a 
prospective observational cohort study. Al-
iment Pharmacol Ther. 2016 Jan; 43(2): 
252–61.
60 Setshedi M, Epstein D, Winter TA, Myer L, 
Watermeyer G, Hift R. Use of thiopurines in 
the treatment of inflammatory bowel disease 
is associated with an increased risk of non-
melanoma skin cancer in an at-risk popula-
tion: a cohort study. J Gastroenterol Hepa-
tol. 2012 Feb; 27(2): 385–9.
61 Hagen JW, Pugliano-Mauro MA. Nonmela-
noma Skin Cancer Risk in Patients With In-
flammatory Bowel Disease Undergoing 
Thiopurine Therapy: A Systematic Review 
of the Literature. Dermatol Surg. 2018 Apr; 
44(4): 469–80.
62 González-Lama Y, Taxonera C, López-San-
román A, Pérez-Calle JL, Bermejo F, Pajares 
R, et al.; Madrid Group for Study of Inflam-
matory Bowel Diseases (ENICMAD). Meth-
otrexate in inflammatory bowel disease: a 
multicenter retrospective study focused on 
long-term efficacy and safety. The Madrid 
experience. Eur J Gastroenterol Hepatol. 
2012 Sep; 24(9): 1086–91.
63 Köller MD, Aletaha D, Funovits J, Pangan A, 
Baker D, Smolen JS. Response of elderly pa-
tients with rheumatoid arthritis to metho-
trexate or TNF inhibitors compared with 
younger patients. Rheumatology (Oxford). 
2009 Dec; 48(12): 1575–80.
64 Din S, Dahele A, Fennel J, Aitken S, Shand 
AG, Arnott ID, et al. Use of methotrexate in 
refractory Crohn’s disease: the Edinburgh 
experience. Inflamm Bowel Dis. 2008 Jun; 
14(6): 756–62.
65 Huang Z, Chao K, Li M, Zhi M, Tang J, Hu 
P, et al. Methotrexate for Refractory Crohn’s 
Disease Compared with Thiopurines: A Ret-
rospective Non-head-to-head Controlled 
Study. Inflamm Bowel Dis. 2017 Mar; 23(3): 
440–7.
66 Colman RJ, Rubin DT. Optimal doses of 
methotrexate combined with anti-TNF 
therapy to maintain clinical remission in in-
flammatory bowel disease. J Crohn’s Colitis. 
2015 Apr; 9(4): 312–7.
67 Herfarth H, Barnes EL, Valentine JF, Han-
son J, Higgins PDR, Isaacs KL, et al. Metho-
trexate Is Not Superior to Placebo in Main-
taining Steroid-Free Response or Remission 
in Ulcerative Colitis. Gastroenterology. 2018 
Oct; 155(4): 1098–108.e9.
68 Oren R, Arber N, Odes S, Moshkowitz M, 
Keter D, Pomeranz I, et al. Methotrexate in 
chronic active ulcerative colitis: a double-
blind, randomized, Israeli multicenter trial. 
Gastroenterology. 1996 May; 110(5): 1416–
21.
69 Seinen ML, Ponsioen CY, de Boer NK, Old-
enburg B, Bouma G, Mulder CJ, et al. Sus-
tained clinical benefit and tolerability of 
methotrexate monotherapy after thiopurine 
therapy in patients with Crohn’s disease. 
Clin Gastroenterol Hepatol. 2013 Jun; 11(6): 
667–72.
70 Kornbluth A, Present DH, Lichtiger S, 
Hanauer S. Cyclosporin for severe ulcerative 
colitis: a user’s guide. Am J Gastroenterol. 
1997 Sep; 92(9): 1424–8.
71 Lobatón T, Ferrante M, Rutgeerts P, Ballet 
V, Van Assche G, Vermeire S. Efficacy and 
safety of anti-TNF therapy in elderly pa-
tients with inflammatory bowel disease. 
Aliment Pharmacol Ther. 2015 Aug; 42(4): 
441–51.
72 Weber NK, Bruining DH, Loftus EV Jr, Tre-
maine WJ, Augustin JJ, Becker BD, et al. 
Comparative outcomes of younger and old-
er hospitalized patients with inflammatory 
bowel disease treated with corticosteroids. 
Inflamm Bowel Dis. 2013 Nov; 19(12): 2644–
51.
73 Cottone M, Kohn A, Daperno M, Armuzzi 
A, Guidi L, D’Inca R, et al. Advanced age is 
an independent risk factor for severe infec-
tions and mortality in patients given anti-
tumor necrosis factor therapy for inflamma-
tory bowel disease. Clin Gastroenterol Hep-
atol. 2011 Jan; 9(1): 30–5.
74 Desai A, Zator ZA, de Silva P, Nguyen DD, 
Korzenik J, Yajnik V, et al. Older age is as-
sociated with higher rate of discontinuation 
of anti-TNF therapy in patients with inflam-
matory bowel disease. Inflamm Bowel Dis. 
2013 Feb; 19(2): 309–15.
75 Shivaji UN, Sharratt CL, Thomas T, Smith 
SC, Iacucci M, Moran GW, et al. Review ar-
ticle: managing the adverse events caused by 
anti-TNF therapy in inflammatory bowel 
disease. Aliment Pharmacol Ther. 2019 Mar; 
49(6): 664–80.
76 Pallavicini FB, Caporali R, Sarzi-Puttini P, 
Atzeni F, Bazzani C, Gorla R, et al. Tumour 
necrosis factor antagonist therapy and can-
cer development: analysis of the LORHEN 
registry. Autoimmun Rev. 2010 Jan; 9(3): 
175–80.
77 Strangfeld A, Hierse F, Rau R, Burmester 
GR, Krummel-Lorenz B, Demary W, et al. 
Risk of incident or recurrent malignancies 
among patients with rheumatoid arthritis 
exposed to biologic therapy in the German 
biologics register RABBIT. Arthritis Res 
Ther. 2010; 12(1):R5.
78 Herrinton LJ, Liu L, Weng X, Lewis JD, Hut-
fless S, Allison JE. Role of thiopurine and 
anti-TNF therapy in lymphoma in inflam-
matory bowel disease. Am J Gastroenterol. 
2011 Dec; 106(12): 2146–53.
79 Siegel CA, Marden SM, Persing SM, Larson 
RJ, Sands BE. Risk of lymphoma associated 
with combination anti-tumor necrosis fac-
tor and immunomodulator therapy for the 
treatment of Crohn’s disease: a meta-analy-
sis. Clin Gastroenterol Hepatol. 2009 Aug; 
7(8): 874–81.
80 Bernstein CN, Blanchard JF, Kliewer E, Wa-
jda A. Cancer risk in patients with inflam-
matory bowel disease: a population-based 
study. Cancer. 2001 Feb; 91(4): 854–62.
81 Kopylov U, Vutcovici M, Kezouh A, Seid-
man E, Bitton A, Afif W. Risk of Lymphoma, 
Colorectal and Skin Cancer in Patients with 
IBD Treated with Immunomodulators and 
Biologics: A Quebec Claims Database Study. 
Inflamm Bowel Dis. 2015 Aug; 21(8): 1847–
53.
82 Long MD, Martin CF, Pipkin CA, Herfarth 
HH, Sandler RS, Kappelman MD. Risk of 
melanoma and nonmelanoma skin cancer 
among patients with inflammatory bowel 
disease. Gastroenterology. 2012 Aug; 143(2): 
390–9.e1.
83 Chen Y, Friedman M, Liu G, Deodhar 
A, Chu CQ. Do tumor necrosis factor in-
hibitors increase cancer risk in patients 
with chronic immune-mediated inflamma-
tory disorders? Cytokine. 2018 Jan; 101: 78–
88.
84 Dixon WG, Watson KD, Lunt M, Mercer 
LK, Hyrich KL, Symmons DP; British Soci-
ety For Rheumatology Biologics Register 
Control Centre Consortium; British Society 
for Rheumatology Biologics Register. Influ-
ence of anti-tumor necrosis factor therapy 
on cancer incidence in patients with rheu-
matoid arthritis who have had a prior malig-
nancy: results from the British Society for 
Rheumatology Biologics Register. Arthritis 
Care Res (Hoboken). 2010 Jun; 62(6): 755–
63.
85 Pache I, Rogler G, Felley C. TNF-alpha 
blockers in inflammatory bowel diseases: 
practical consensus recommendations and a 






86 Feagan BG, Rutgeerts P, Sands BE, Hanauer 
S, Colombel JF, Sandborn WJ, et al.; GEMI-
NI 1 Study Group. Vedolizumab as induc-
tion and maintenance therapy for ulcerative 
colitis. N Engl J Med. 2013 Aug; 369(8): 699–
710.
87 Sandborn WJ, Feagan BG, Rutgeerts P, 
Hanauer S, Colombel JF, Sands BE, et al.; 
GEMINI 2 Study Group. Vedolizumab as in-
duction and maintenance therapy for 
Crohn’s disease. N Engl J Med. 2013 Aug; 
369(8): 711–21.
88 Navaneethan U, Edminister T, Zhu X, Kom-
maraju K, Glover S. Vedolizumab Is Safe and 
Effective in Elderly Patients with Inflamma-
tory Bowel Disease. Inflamm Bowel Dis. 
2017 Apr; 23(4):E17.
89 Colombel JF, Sands BE, Rutgeerts P, Sand-
born W, Danese S, D’Haens G, et al. The 
safety of vedolizumab for ulcerative colitis 
and Crohn’s disease. Gut. 2017 May; 66(5): 
839–51.
90 Feagan BG, Sandborn WJ, Gasink C, Jacob-
stein D, Lang Y, Friedman JR, et al.; UNITI–
IM-UNITI Study Group. Ustekinumab as 
Induction and Maintenance Therapy for 
Crohn’s Disease. N Engl J Med. 2016 Nov; 
375(20): 1946–60.
91 Sandborn WJ, Su C, Sands BE, D’Haens GR, 
Vermeire S, Schreiber S, et al.; OCTAVE In-
duction 1, OCTAVE Induction 2, and OC-
TAVE Sustain Investigators. Tofacitinib as 
Induction and Maintenance Therapy for Ul-
cerative Colitis. N Engl J Med. 2017 May; 
376(18): 1723–36.
92 Sandborn WJ, Panes J, D’Haens GR, 
Sands  BE, Su C, Moscariello M, et al. 
 Safety   of Tofacitinib for Treatment of 
 Ulcerative Colitis, Based on 4.4 Years of 
Data From Global Clinical Trials. Clin 
Gastroenterol Hepatol. 2019 Jul; 17(8): 
1541–50.
93 Winthrop KL, Curtis JR, Lindsey S, Tana-
ka  Y, Yamaoka K, Valdez H, et al. Her-
pes  Zoster and Tofacitinib: Clinical Out-
comes and the Risk of Concomitant Ther-
apy. Arthritis Rheumatol. 2017 Oct; 69(10): 
1960–8.
94 Cunningham AL, Lal H, Kovac M, Chlibek 
R, Hwang SJ, Díez-Domingo J, et al.; ZOE-
70 Study Group. Efficacy of the Herpes Zos-
ter Subunit Vaccine in Adults 70 Years of 
Age or Older. N Engl J Med. 2016 Sep; 
375(11): 1019–32.
95 Kovac M, Lal H, Cunningham AL, Levin MJ, 
Johnson RW, Campora L, et al.; ZOE-50/70 
Study Group. Complications of herpes zos-
ter in immunocompetent older adults: inci-
dence in vaccine and placebo groups in two 
large phase 3 trials. Vaccine. 2018 Mar; 
36(12): 1537–41.
96 Ananthakrishnan AN, Issa M, Beaulieu DB, 
Skaros S, Knox JF, Lemke K, et al. History of 
medical hospitalization predicts future need 
for colectomy in patients with ulcerative 
colitis. Inflamm Bowel Dis. 2009 Feb; 15(2): 
176–81.
 97 Ha CY, Newberry RD, Stone CD, Ciorba 
MA. Patients with late-adult-onset ulcer-
ative colitis have better outcomes than those 
with early onset disease. Clin Gastroenterol 
Hepatol. 2010 Aug; 8(8): 682–7.e1.
 98 Longo WE, Virgo KS, Bahadursingh 
AN,  Johnson FE. Patterns of disease and 
surgical treatment among United States 
veterans more than 50 years of age with ul-
cerative colitis. Am J Surg. 2003 Nov; 
186(5): 514–8.
 99 Triantafillidis JK, Emmanouilidis A, Pomo-
nis E, Cheracakis P, Hereti I, Merikas E, et al. 
Ulcerative colitis in the elderly: clinical pat-
terns and outcome in 51 Greek patients. J 
Gastroenterol. 2001 May; 36(5): 312–6.
100 Polito JM 2nd, Childs B, Mellits ED, Tokay-
er AZ, Harris ML, Bayless TM. Crohn’s dis-
ease: influence of age at diagnosis on site and 
clinical type of disease. Gastroenterology. 
1996 Sep; 111(3): 580–6.
101 Tremaine WJ, Timmons LJ, Loftus EV Jr, 
Pardi DS, Sandborn WJ, Harmsen WS, et al. 
Age at onset of inflammatory bowel disease 
and the risk of surgery for non-neoplastic 
bowel disease. Aliment Pharmacol Ther. 
2007 Jun; 25(12): 1435–41.
102 Navaneethan U, Parasa S, Venkatesh PG, 
Trikudanathan G, Shen B. Prevalence and 
risk factors for colonic perforation during 
colonoscopy in hospitalized inflammatory 
bowel disease patients. J Crohn’s Colitis. 
2011 Jun; 5(3): 189–95.
103 Chapman JR, Larson DW, Wolff BG, Dozois 
EJ, Cima RR, Pemberton JH, et al. Ileal 
pouch-anal anastomosis: does age at the 
time of surgery affect outcome? Arch Surg. 
2005 Jun; 140(6): 534–9.
104 Delaney CP, Fazio VW, Remzi FH, Hammel 
J, Church JM, Hull TL, et al. Prospective, 
age-related analysis of surgical results, func-
tional outcome, and quality of life after ileal 
pouch-anal anastomosis. Ann Surg. 2003 
Aug; 238(2): 221–8.
105 Ananthakrishnan AN, McGinley EL, Binion 
DG. Inflammatory bowel disease in the el-
derly is associated with worse outcomes: a 
national study of hospitalizations. Inflamm 
Bowel Dis. 2009 Feb; 15(2): 182–9.
106 Turrentine FE, Wang H, Simpson VB, Jones 
RS. Surgical risk factors, morbidity, and 
mortality in elderly patients. J Am Coll Surg. 
2006 Dec; 203(6): 865–77.
107 Almogy G, Sachar DB, Bodian CA, Green-
stein AJ. Surgery for ulcerative colitis in el-
derly persons: changes in indications for 
surgery and outcome over time. Arch Surg. 
2001 Dec; 136(12): 1396–400.
108 Page MJ, Poritz LS, Kunselman SJ, Koltun 
WA. Factors affecting surgical risk in elder-
ly patients with inflammatory bowel dis-
ease. J Gastrointest Surg. 2002 Jul-Aug; 6(4): 
606–13.
109 Halmos EP, Gibson PR. Dietary manage-
ment of IBD—insights and advice. Nat Rev 
Gastroenterol Hepatol. 2015 Mar; 12(3): 
133–46.
110 Massironi S, Rossi RE, Cavalcoli FA, Della 
Valle S, Fraquelli M, Conte D. Nutritional 
deficiencies in inflammatory bowel disease: 
therapeutic approaches. Clin Nutr. 2013 
Dec; 32(6): 904–10.
111 Mijac DD, Janković GL, Jorga J, Krstić MN. 
Nutritional status in patients with active in-
flammatory bowel disease: prevalence of 
malnutrition and methods for routine nutri-
tional assessment. Eur J Intern Med. 2010 
Aug; 21(4): 315–9.
112 Long MD, Martin C, Sandler RS, Kappel-
man MD. Increased risk of pneumonia 
among patients with inflammatory bowel 
disease. Am J Gastroenterol. 2013 Feb; 
108(2): 240–8.
113 Long MD, Martin C, Sandler RS, Kappelman 
MD. Increased risk of herpes zoster among 
108 604 patients with inflammatory bowel 
disease. Aliment Pharmacol Ther. 2013 Feb; 
37(4): 420–9.
114 Tinsley A, Navabi S, Williams ED, Liu G, 
Kong L, Coates MD, et al. Increased Risk of 
Influenza and Influenza-Related Complica-
tions Among 140,480 Patients With Inflam-
matory Bowel Disease. Inflamm Bowel Dis. 
2019 Jan; 25(2): 369–76.
115 Toruner M, Loftus EV Jr, Harmsen WS, 
Zinsmeister AR, Orenstein R, Sandborn 
WJ, et al. Risk factors for opportunistic in-
fections in patients with inflammatory 
bowel disease. Gastroenterology. 2008 Apr; 
134(4): 929–36.
116 Click B, Regueiro M. Managing Risks with 
Biologics. Curr Gastroenterol Rep. 2019 Jan; 
21(2): 1.
117 Farraye FA, Melmed GY, Lichtenstein GR, 
Kane SV. ACG Clinical Guideline: Preven-
tive Care in Inflammatory Bowel Disease. 
Am J Gastroenterol. 2017 Feb; 112(2): 241–
58.
118 Moscandrew M, Mahadevan U, Kane S. 
General health maintenance in IBD. In-
flamm Bowel Dis. 2009 Sep; 15(9): 1399–
409.
119 Rubin LG, Levin MJ, Ljungman P, Davies 
EG, Avery R, Tomblyn M, et al.; Infectious 
Diseases Society of America. 2013 IDSA 
clinical practice guideline for vaccination of 
the immunocompromised host. Clin Infect 
Dis. 2014 Feb; 58(3): 309–18.
120 Papa A, Gerardi V, Marzo M, Felice C, Ra-
paccini GL, Gasbarrini A. Venous thrombo-
embolism in patients with inflammatory 
bowel disease: focus on prevention and 
treatment. World J Gastroenterol. 2014 Mar; 
20(12): 3173–9.
121 Kandiel A, Fraser AG, Korelitz BI, Brensing-
er C, Lewis JD. Increased risk of lymphoma 
among inflammatory bowel disease patients 
treated with azathioprine and 6-mercapto-
purine. Gut. 2005 Aug; 54(8): 1121–5.
122 Hemmens VJ, Moore DE. Photochemical 
sensitization by azathioprine and its metab-
olites—II. Azathioprine and nitroimidazole 
metabolites. Photochem Photobiol. 1986 
Mar; 43(3): 257–62.
Elderly IBD Patient 15Digestion
DOI: 10.1159/000503099
123 O’Donovan P, Perrett CM, Zhang X, Mon-
taner B, Xu YZ, Harwood CA, et al. Azathio-
prine and UVA light generate mutagenic 
oxidative DNA damage. Science. 2005 Sep; 
309(5742): 1871–4.
124 Beigel F, Steinborn A, Schnitzler F, Tillack C, 
Breiteneicher S, John JM, et al. Risk of ma-
lignancies in patients with inflammatory 
bowel disease treated with thiopurines or 
anti-TNF alpha antibodies. Pharmacoepide-
miol Drug Saf. 2014 Jul; 23(7): 735–44.
125 Rungoe C, Simonsen J, Riis L, Frisch M, 
Langholz E, Jess T. Inflammatory bowel dis-
ease and cervical neoplasia: a population-
based nationwide cohort study. Clin Gastro-
enterol Hepatol. 2015 Apr; 13(4): 693–700.
e1.
126 Pandey N, Herrera HH, Johnson CM, Mac-
Carthy AA, Copeland LA. Preventative care 
for patients with inflammatory bowel dis-
ease in the Veterans Health Administration. 
Medicine (Baltimore). 2016 Jul; 95(27):e4012.
127 Annese V, Daperno M, Rutter MD, Amiot 
A, Bossuyt P, East J, et al.; European Crohn’s 
and Colitis Organisation. European evi-
dence based consensus for endoscopy in in-
flammatory bowel disease. J Crohn’s Colitis. 
2013 Dec; 7(12): 982–1018.
128 Baars JE, Kuipers EJ, van Haastert M, Nico-
laï JJ, Poen AC, van der Woude CJ. Age 
at  diagnosis of inflammatory bowel dis-
ease  influences early development of 
colorectal cancer in inflammatory bowel 
disease patients: a nationwide, long-term 
survey. J Gastroenterol. 2012 Dec; 47(12): 
1308–22.
129 Shi HY, Chan FK, Leung WK, Li MK, Leung 
CM, Sze SF, et al. Natural History of Elderly-
onset Ulcerative Colitis: Results from a Ter-
ritory-wide Inflammatory Bowel Disease 
Registry. J Crohn’s Colitis. 2016 Feb; 10(2): 
176–85.
